美国92例皮肤疾病的UVA1光疗经验
UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States.
作者信息
Tuchinda Chanisada, Kerr Holly A, Taylor Charles R, Jacobe Heidi, Bergamo Bettany M, Elmets Craig, Rivard Jennifer, Lim Henry W
机构信息
Department of Dermatology, Henry Ford Hospital, Detroit, MI 48202, USA.
出版信息
Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):247-53. doi: 10.1111/j.1600-0781.2006.00245.x.
BACKGROUND
The efficacy and safety of UVA1 (340-400 nm) phototherapy were established by studies from European countries.
PURPOSE
Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States.
METHODS
A retrospective analysis of 92 cases of UVA1-treated cutaneous conditions from four medical centers in the United States was performed.
RESULTS
Two-third of the patients showed a fair to good response (26-100% improvement) and one-third of the patients showed a poor response (0-25% improvement). Diseases with a moderate to good response (51-100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium- to high-dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I-III responded better that those with a darker skin type.
CONCLUSION
UVA1 phototherapy is a useful and well-tolerated treatment option for a variety of skin conditions.
背景
欧洲国家的研究证实了UVA1（340 - 400纳米）光疗的有效性和安全性。
目的
评估美国皮肤疾病患者接受UVA1光疗的经验。
方法
对美国四个医疗中心92例接受UVA1治疗的皮肤疾病患者进行回顾性分析。
结果
三分之二的患者显示出中等至良好的反应（改善26% - 100%），三分之一的患者显示出较差的反应（改善0% - 25%）。反应中等至良好（改善51% - 100%）的疾病包括成人硬肿病、手足皮炎、特应性皮炎、硬斑病（中等或中高剂量UVA1）、系统性硬化症和色素性荨麻疹。除了皮肤变黑外，15%的患者出现了其他不良反应，包括瘙痒、红斑、压痛和烧灼感。皮肤类型为I - III型的患者比皮肤类型较深的患者反应更好。
结论
UVA1光疗是治疗多种皮肤疾病的一种有用且耐受性良好的治疗选择。
Zotero 插件